{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:31:48Z","timestamp":1752550308003},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00108-024-01729-9","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T06:01:56Z","timestamp":1718258516000},"page":"672-680","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Klinisch aktive Hypophysentumoren","Clinically active pituitary tumors"],"prefix":"10.1007","volume":"65","author":[{"given":"Nicole","family":"Unger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marily","family":"Theodoropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Schilbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"1729_CR1","doi-asserted-by":"publisher","first-page":"e13111","DOI":"10.1111\/jne.13111","volume":"34","author":"M Balomenaki","year":"2022","unstructured":"Balomenaki\u00a0M, Margaritopoulos\u00a0D, Vassiliadi\u00a0DA, Tsagarakis\u00a0S (2022) Diagnostic workup of Cushing\u2019s syndrome. J\u00a0Neuroendocrinol 34:e13111. https:\/\/doi.org\/10.1111\/jne.13111","journal-title":"J Neuroendocrinol"},{"key":"1729_CR2","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s40618-019-01066-x","volume":"42","author":"P Beck-Peccoz","year":"2019","unstructured":"Beck-Peccoz\u00a0P, Giavoli\u00a0C, Lania\u00a0A (2019) A 2019 update on TSH-secreting pituitary adenomas. J\u00a0Endocrinol Invest 42:1401\u20131406. https:\/\/doi.org\/10.1007\/s40618-019-01066-x","journal-title":"J Endocrinol Invest"},{"key":"1729_CR3","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1210\/jc.2013-3059","volume":"99","author":"M Bidlingmaier","year":"2014","unstructured":"Bidlingmaier\u00a0M, Friedrich\u00a0N, Emeny\u00a0RT et\u00a0al (2014) Reference intervals for insulin-like growth factor\u20111 (igf-i) from birth to senescence: results from a\u00a0multicenter study using a\u00a0new automated chemiluminescence IGF\u2011I immunoassay conforming to recent international recommendations. J\u00a0Clin Endocrinol Metab 99:1712\u20131721. https:\/\/doi.org\/10.1210\/jc.2013-3059","journal-title":"J Clin Endocrinol Metab"},{"key":"1729_CR4","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-22-0440","volume":"187","author":"P Burman","year":"2022","unstructured":"Burman\u00a0P, Trouillas\u00a0J, Losa\u00a0M et\u00a0al (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187:593\u2013605. https:\/\/doi.org\/10.1530\/EJE-22-0440","journal-title":"Eur J Endocrinol"},{"key":"1729_CR5","first-page":"675","volume":"15","author":"BW Chong","year":"1994","unstructured":"Chong\u00a0BW, Kucharczyk\u00a0W, Singer\u00a0W, George\u00a0S (1994) Pituitary gland MR: a\u00a0comparative study of healthy volunteers and patients with microadenomas. AJNR Am J Neuroradiol 15:675\u2013679","journal-title":"AJNR Am J Neuroradiol"},{"key":"1729_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/cen.14706","volume":"97","author":"EC Coopmans","year":"2022","unstructured":"Coopmans\u00a0EC, Korbonits\u00a0M (2022) Molecular genetic testing in the management of pituitary disease. Clin Endocrinol (oxf) 97:424\u2013435. https:\/\/doi.org\/10.1111\/cen.14706","journal-title":"Clin Endocrinol (oxf)"},{"key":"1729_CR7","doi-asserted-by":"publisher","first-page":"e220291","DOI":"10.1530\/JOE-22-0291","volume":"257","author":"SMC De Sousa","year":"2023","unstructured":"De Sousa\u00a0SMC, Lenders\u00a0NF, Lamb\u00a0LS et\u00a0al (2023) Pituitary tumours: molecular and genetic aspects. J\u00a0Endocrinol 257:e220291. https:\/\/doi.org\/10.1530\/JOE-22-0291","journal-title":"J Endocrinol"},{"key":"1729_CR8","doi-asserted-by":"publisher","unstructured":"Fleseriu M, Auchus R, Bancos I et\u00a0al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a\u00a0guideline update. Lancet Diabetes Endocrinol 9:847\u2013875. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","DOI":"10.1016\/S2213-8587(21)00235-7"},{"key":"1729_CR9","doi-asserted-by":"publisher","unstructured":"Fleseriu M, Biller BMK, Freda PU et\u00a0al (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24:1\u201313. https:\/\/doi.org\/10.1007\/s11102-020-01091-7","DOI":"10.1007\/s11102-020-01091-7"},{"key":"1729_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina\u00a0A, Barkhoudarian\u00a0G, Beckers\u00a0A et\u00a0al (2020) Multidisciplinary management of acromegaly: A\u00a0consensus. Rev Endocr Metab Disord 21:667\u2013678. https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev Endocr Metab Disord"},{"key":"1729_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11102-023-01345-0","volume":"26","author":"A Giustina","year":"2023","unstructured":"Giustina\u00a0A, Uygur\u00a0MM, Frara\u00a0S et\u00a0al (2023) Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE). Results Audit Lead Int Centers Pituit 26:583\u2013596. https:\/\/doi.org\/10.1007\/s11102-023-01345-0","journal-title":"Results Audit Lead Int Centers Pituit"},{"key":"1729_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.7326\/0003-4819-120-10-199405150-00001","volume":"120","author":"WA Hall","year":"1994","unstructured":"Hall\u00a0WA, Luciano\u00a0MG, Doppman\u00a0JL et\u00a0al (1994) Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med 120:817\u2013820. https:\/\/doi.org\/10.7326\/0003-4819-120-10-199405150-00001","journal-title":"Ann Intern Med"},{"key":"1729_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1530\/EJE-22-0647","volume":"187","author":"MD Ilie","year":"2022","unstructured":"Ilie\u00a0MD, Villa\u00a0C, Cuny\u00a0T et\u00a0al (2022) Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a\u00a0cohort study. Eur J Endocrinol 187:685\u2013696. https:\/\/doi.org\/10.1530\/EJE-22-0647","journal-title":"Eur J Endocrinol"},{"key":"1729_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ecl.2007.10.011","volume":"37","author":"ME Molitch","year":"2008","unstructured":"Molitch\u00a0ME (2008) Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am 37:151\u2013171","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1729_CR15","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn\u00a0S, Fleseriu\u00a0M, Casanueva\u00a0FF et\u00a0al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a\u00a0Pituitary Society international Consensus Statement. Nat Rev Endocrinol 19:722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"key":"1729_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11154-020-09554-9","volume":"21","author":"S Petersenn","year":"2020","unstructured":"Petersenn\u00a0S, Heaney\u00a0AP (2020) Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas. Rev Endocr Metab Disord 21:277\u2013286. https:\/\/doi.org\/10.1007\/s11154-020-09554-9","journal-title":"Rev Endocr Metab Disord"},{"key":"1729_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00327890","volume":"28","author":"RG Peyster","year":"1986","unstructured":"Peyster\u00a0RG, Adler\u00a0LP, Viscarello\u00a0RR et\u00a0al (1986) CT of the normal pituitary gland. Neuroradiology 28:161\u2013165. https:\/\/doi.org\/10.1007\/BF00327890","journal-title":"Neuroradiology"},{"key":"1729_CR18","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0338","author":"P Raymond","year":"2023","unstructured":"Raymond\u00a0P, Raverot\u00a0G, Ilie\u00a0M\u2011D (2023) Outcome and prognostic factors for pituitary carcinomas: lessons from a\u00a0systematic review. Endocr Relat Cancer. https:\/\/doi.org\/10.1530\/ERC-22-0338","journal-title":"Endocr Relat Cancer"},{"key":"1729_CR19","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1210\/clinem\/dgac492","volume":"107","author":"M Savas","year":"2022","unstructured":"Savas\u00a0M, Mehta\u00a0S, Agrawal\u00a0N et\u00a0al (2022) Approach to the Patient: Diagnosis of Cushing Syndrome. J\u00a0Clin Endocrinol Metab 107:3162\u20133174. https:\/\/doi.org\/10.1210\/clinem\/dgac492","journal-title":"J Clin Endocrinol Metab"},{"key":"1729_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1530\/EJE-19-0139","volume":"181","author":"K Schilbach","year":"2019","unstructured":"Schilbach\u00a0K, Gar\u00a0C, Lechner\u00a0A et\u00a0al (2019) Determinants of the growth hormone nadir during oral glucose tolerance test in adults. Eur J Endocrinol 181:55\u201367. https:\/\/doi.org\/10.1530\/EJE-19-0139","journal-title":"Eur J Endocrinol"},{"key":"1729_CR21","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/ejendo\/lvad114","volume":"189","author":"J Simon","year":"2023","unstructured":"Simon\u00a0J, Perez-Rivas\u00a0LG, Zhao\u00a0Y et\u00a0al (2023) Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours. Eur J Endocrinol 189:372\u2013378. https:\/\/doi.org\/10.1093\/ejendo\/lvad114","journal-title":"Eur J Endocrinol"},{"key":"1729_CR22","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11102-022-01253-9","volume":"25","author":"M Theodoropoulou","year":"2022","unstructured":"Theodoropoulou\u00a0M, Reincke\u00a0M (2022) Genetics of Cushing\u2019s disease: from the lab to clinical practice. Pituitary 25:689\u2013692. https:\/\/doi.org\/10.1007\/s11102-022-01253-9","journal-title":"Pituitary"},{"key":"1729_CR23","doi-asserted-by":"publisher","unstructured":"Trouillas\u00a0J, Roy\u00a0P, Sturm\u00a0N, Dantony\u00a0E, Cortet-Rudelli\u00a0C, Viennet\u00a0G, Bonneville\u00a0JF, Assaker\u00a0R, Auger\u00a0C, Brue\u00a0T, Cornelius\u00a0A, Dufour\u00a0H, Jouanneau\u00a0E, Fran\u00e7ois\u00a0P, Galland\u00a0F, Mougel\u00a0F, Chapuis\u00a0F, Villeneuve\u00a0L, Maurage\u00a0CA, Figarella-Branger\u00a0D, Raverot\u00a0G; members of HYPOPRONOS; Barlier\u00a0A, Bernier\u00a0M, Bonnet\u00a0F, Borson-Chazot\u00a0F, Brassier\u00a0G, Caulet-Maugendre\u00a0S, Chabre\u00a0O, Chanson\u00a0P, Cottier\u00a0JF, Delemer\u00a0B, Delgrange\u00a0E, Di Tommaso\u00a0L, Eimer\u00a0S, Gaillard\u00a0S, Jan\u00a0M, Girard\u00a0JJ, Lapras\u00a0V, Loiseau\u00a0H, Passagia\u00a0JG, Patey\u00a0M, Penfornis\u00a0A, Poirier\u00a0JY, Perrin\u00a0G, Tabarin\u00a0A (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123\u2013135. https:\/\/doi.org\/10.1007\/s00401-013-1084-y. Epub 2013 Feb 12. PMID: 23400299https:\/\/doi.org\/10.1007\/s00401-013-1084-y","DOI":"10.1007\/s00401-013-1084-y 10.1007\/s00401-013-1084-y"},{"key":"1729_CR24","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1093\/ejendo\/lvad042","volume":"188","author":"J Trouillas","year":"2023","unstructured":"Trouillas\u00a0J, Burman\u00a0P, Losa\u00a0M et\u00a0al (2023) Initial pathology in aggressive pituitary tumours and carcinomas: 2b or not 2b?\u2014that is the question. Eur J Endocrinol 188:C1\u2013C5. https:\/\/doi.org\/10.1093\/ejendo\/lvad042","journal-title":"Eur J Endocrinol"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01729-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01729-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01729-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:03:26Z","timestamp":1719385406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01729-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1729"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01729-9","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]},"assertion":[{"value":"15 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0Unger hat innerhalb der letzten drei Jahre Zuwendungen folgender Institutionen f\u00fcr Vortrags- und Beratert\u00e4tigkeiten erhalten: Sandoz\/Hexal AG, Recordati Rare Diseases Germany GmbH, HRA Pharma. K.\u00a0Schilbach hat innerhalb der letzten drei Jahre Zuwendungen folgender Institutionen f\u00fcr Forschung und Studien sowie f\u00fcr Vortrags- und Beratert\u00e4tigkeiten erhalten: Sandoz\/Hexal AG, Recordati Rare Diseases Germany GmbH, Pfizer Pharma GmbH, Consilient Health, Ascendis Pharma A\/S. M.\u00a0Theodoropoulou gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}